Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
A car-sharing platform for drivers to receive an extra income by allowing the local community to drive their cars instead of leaving it idle and unused. Hiyacar has a acquired an exclusive insurance product with AXA and already has more than 2,000 cars enrolled, with the majority located in London and surrounding urban areas with the intention of expanding further in the future.
days to go:
Expired
investment:
£1,431,885
Troubadour is a London-based menswear brand specialising in designing minimalist bags & accessories by combining performance design with a clean & modern aesthetic feel. The company has delivered its products to 60+ wholesalers. It is backed by Pembroke VCT, a luxury-focused venture capital firm based in London. Troubadour is planning to work with non-traditional retailers including Ritz Carlton, Four Seasons, and Equinox. It has also collaborated with many world-renowned brands such as British tailors 'Thom Sweeney' and British essentials brand 'Sunspel' that is famous for clothing James Bond. The company has also been a case study for classes at the Harvard Business School. With the investment, the company will support sales growth to its customers and retail partners and also fund working capital requirements from its forecast growth plan.
days to go:
Expired
investment:
£621,240
Callaly is the UK’s first female care B-Corp that delivers subscription-based organic cotton period products. The company has invented and patented the 'Tampliner', a combination of an organic cotton tampon with a soft mini-liner for built-in leak protection, with a clean insertion and removal, and no hard plastic applicator. It is multi-patented in 30 countries. The company has developed bespoke robotic machinery to automate production at a UK facility. In a £26 billion global femcare market, Callaly claims that its potential tampliner market would constitute 2% to 4% by 2024. The company has received rave reviews from magazines such as Cosmopolitan and Grazia. Callaly plans to begin sales in Europe in the third quarter of 2020 followed by sales in the US and Asia in 2021.
days to go:
Expired
investment:
£1,704,460
Founded in 2012, Holly and Beau is an award-winning kids-wear brand which offers a unique collection of colour changing rainwear. The company sells its products directly through its website and via distributors in the UK, the US, Europe and South Korea. Holly and Beau is in the process of patenting its technology, which will enable it to develop a unique product range of rainwear and skiwear. Moreover, the company has successfully maintained an average revenue growth of 80%-100% YOY.
days to go:
Expired
investment:
£218,570
Actve is on a mission to change the way people connect with their favourite fitness creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.
days to go:
Expired
investment:
£165,627
